AZD2171 in Treating Young Patients With Previousley untreatable Primary CNS Tumours

• Conditions: Recurrent, Progressive, or Refactory Primary CNS Tumours; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2012-001154-26-Outside-EU/EEA
• Lead Sponsor: Pediatric Brain Tumour Consortium

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03-09
• Last Update Posted: 20 March 2012

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

Patients must be less than or equal to 21

Histology confirmed primary CNS tumour

Recurrent, progressive, or refactory disease

No known curative therapy available
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients with any clincially significant unrelated systemic illness

Patients receiving any other anticancer or investigational drug therapy

Patients, ages 1-17, with uncontrolled hypertension

Patients with prior treatment with AZD2171

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified